Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-168 monotherapy in relapsed or refractory mantle cell lymphoma
CTR20230100Phase 2Completed
- Sponsor
- Lupeng Pharmaceutical
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rocbrutinib in mantle cell lymphoma (MCL), sponsored by Lupeng Pharmaceutical. Started Jan 2023; status: completed.
02
Drugs
rocbrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20230100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230100.